Introduction
Hepatocellular carcinoma (HCC) accounts for 95% of primary liver cancer 1 and is the second most common cause of cancer-associated death worldwide. 2 Liver resection and liver transplantation are the only curative treatments for HCC. The majority of patients, however, are not eligible for either resection or transplantation because of advanced tumor stage, underlying liver dysfunction, and lack of donor organs. Additionally, postoperative recurrence is frequent and can be as high as 25% per year, leading to death of ~80% of patients within 12 months of diagnosis. 3, 4 Other therapeutic options, such as percutaneous chemical, thermal, or radiofrequency ablation (RFA); transarterial chemoembolization (TACE); chemotherapy; and targeted therapy, also have limited efficacy. 5 Therefore, finding effective methods to increase efficacy of treatment and reduce recurrence rate is of utmost importance in the therapy of HCC.
Immunotherapy has been considered as a potential treatment option for HCC for a number of years. 6, 7 Several approaches to immunotherapy for HCC have shown promise 
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Yu et al in early clinical trials. These treatments can be divided into four main categories: immune checkpoint inhibitors, monoclonal antibodies, adoptive cell transfer, and oncolytic virus therapy. 7 Adoptive cytokine-induced killer (CIK) cell transfer is one of the promising avenues of immunotherapy for HCC. CIK cells are non-major histocompatibility complex-restricted cells that exhibit strong cytolytic activities against susceptible tumors 8 and express both T-and natural killer (NK) cell markers, CD3 and CD56, respectively. 9 CIK cells can be generated from human peripheral blood mononuclear cells through induction with interferon-γ, anti-CD3 antibody, and interleukin-2. 8 There are a number of advantages of CIK cells compared with other immune cells. CIK cells have a higher proliferation rate and can be obtained directly from cancer patients. 10 Additionally, CIK cells have strong cytolytic activities and recognize a number of tumors, including those that are resistant to lymphokine-activated killer cells or NK cells. 11 Furthermore, CIK cells were not shown to cause graft-versus-host disease. 7, 8 Therefore, CIK cells present a promising immunotherapy approach that could be used for HCC patients. 12 And indeed, a number of recent clinical trials have demonstrated that adoptive infusion of CIK cells was associated with a substantial antitumor effect in HCC patients. [13] [14] [15] [16] [17] [18] [19] CIK cell transfer was shown to decrease the rate of relapse after TACE and RFA therapy and increase disease-free survival and overall survival for HCC patients after liver resection or TACE. [13] [14] [15] [16] [17] [18] [19] However, despite the increasing evidence pointing to CIK cells as a viable option for HCC treatment, more translational research and clinical trials are needed to provide convincing evidence regarding the efficacy of CIK cell immunotherapy. The aim of the present meta-analysis was to assess the efficacy and safety of CIK cell-based immunotherapy as an adjuvant therapy for HCC.
Materials and methods search strategy
We followed the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) guidance for systematic reviews of observational and diagnostic studies 20 and searched the published literature using the Medline, Cochrane, EMBASE, and Google Scholar databases through November 6, 2015, with various combinations of the following keywords: cytokineinduced killer, CIK, hepatocellular carcinoma, HCC, liver neoplasm, and immunotherapy. The specific search terms were the following: (((hepatocellular carcinoma) OR HCC) OR liver neoplasm) AND ((cytokine-induced killer cell) OR CIK), with the following filters: Humans, Abstract available, Clinical study, Clinical trial, Meta-analysis, Review, and Systematic review.
We manually searched references in relevant publications to identify additional eligible trials. The inclusion criteria were as follows: 1) randomized controlled trials (RCTs) and prospective or retrospective studies; 2) patients who were initially diagnosed with HCC and allocated to either an adoptive immunotherapy group or a control group; and 3) quantitative outcomes (overall survival, progression-free survival, and disease-free survival). The exclusion criteria were as follows: 1) format of cohort study, letter, comment, editorial, case report, proceeding, or personal communication; 2) patients without a diagnosis of HCC; 3) study designed for adoptive immunotherapy with other cell types (eg, NK cells, dendritic cells); and 4) no quantitative outcomes. study selection and data extraction Data were extracted independently by two reviewers. A third reviewer was consulted in case of disagreements. We extracted data on study population (number, age, and gender of patients in each group), study design, length of follow-up time, Child-Pugh Class, cancer stage, viral hepatitis profile, and data for overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS).
Quality assessment
We assessed study quality using the Cochrane Risk of Bias Tool. 21 The quality assessment was performed by two independent reviewers; the third reviewer was consulted if no consensus could be reached. The quality assessment of included studies is presented in Figure 1 .
statistical analysis
The outcomes of interest were OS, PFS, and DFS. Hazard ratios (HR) and 95% confidence intervals (95% CI) reported by individual studies were used as the outcome measures. If not provided in individual studies, the HR and 95% CI were calculated from summary statistics of time-to-event analyses with the methods proposed by Tierney et al. 22 Heterogeneity among the studies was assessed by the Cochran Q and the I 2 statistic. The Q statistic was defined as the weighted sum of the squared deviations of the estimates of all studies; P,0.10 was considered statistically significant for heterogeneity. For the I 2 statistic, which indicated the percentage of the observed between-study variability due to heterogeneity, the ranges used were the following: no heterogeneity (I 2 =0%-25%), moderate heterogeneity (I 2 =25%-50%), large heterogeneity (I 2 =50%-75%), and extreme heterogeneity (I 2 =75%-100%).
The random-effect model (DerSimonian-Laird method) was used to generate pooled estimates across studies for 
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Yu et al each outcome. A two-sided P-value ,0.05 was considered statistically significant. All analyses that were performed were stratified by study design (ie, randomized and nonrandomized trials). To assess whether a single study impacts the pooled results, a sensitivity analysis was performed using the leave-one-out approach. All statistical analyses were performed with the statistical software Comprehensive MetaAnalysis, version 2.0 (Biostat, Englewood, NJ, USA).
Results

Basic characteristics of included studies
After considering the inclusion and exclusion criteria, eight randomized trials, 13, 14, 18, [23] [24] [25] [26] [27] six prospective studies, 15, [28] [29] [30] [31] [32] [33] and three retrospective studies 16, 17, 32 were eligible for this review ( Figure 2 ). The eligible studies analyzed a total of 1,979 patients with HCC, 1,029 of whom underwent adjuvant immunotherapy with CIK cells. The number of patients ranged from 38 to 410 per study. The patients' age ranged from 43 to 56 years. The proportion of male patients ranged from 52.4% to 97.8%. Information regarding patient demographics, liver function, stage of HCC, hepatitis infection, and treatment regimens is summarized in Table 1 . The treatment used by the majority of studies was TACE, either alone (six studies) or in combination with RFA (five studies), percutaneous ethanol injection (one study), or surgery (one study). Surgery was the second most common treatment, used alone (two studies) or with RFA and percutaneous ethanol injection (one study). For all studies, patients who received CIK cell immunotherapy also received the same treatment as the control group.
Outcome measures
A summary of the data for OS, PFS, and DFS is shown in Table 2 
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,50: =47.2%, P=0.019). The overall analysis revealed that patients in the CIK cell-treatment group had a higher survival rate (pooled HR =0.594, 95% CI =0.501-0.703, P,0.001). The results were similar for both RCTs (pooled HR =0.644, 95% CI =0.506-0.820, P,0.001) and non-RCTs (pooled HR =0.548, 95% CI =0.432-0.695, P,0.001) ( Figure 3A) .
One RCT 23 and 4 non-RCTs 15, 16, 28, 33 analyzed the HR for PFS and were included in the meta-analysis. There was no evidence of heterogeneity across individual non-RCT studies (I 2 =0%, P=0.642). Analysis of RCTs revealed that there was no significant difference between the PFS rate in patients with or without CIK treatment (HR =0.700, 95% CI =0.452-1.084, P=0.110). The overall analysis of the non-RCTs indicated a higher rate of PFS in patients treated with CIK cells (pooled HR =0.613, 95% CI =0.510-0.738, P,0.001). The comparison between the pooled results from RCTs and that of non-RCTs ( Figure 3B ) regarding the PFS rate did not reach statistical significance.
One non-RCT 30 and 4 RCTs 13,14,18,24 reported the HR for disease-free survival. There was no evidence of heterogeneity across the four RCTs that were included in the metaanalysis of the disease-free survival rate (I 2 =0%, P=0.781). The overall analysis of RCTs revealed that patients treated with CIK cells had lower rates of relapse or recurrence (pooled HR =0.635, 95% CI =0.514-0.784, P,0.001). Similar results were also found when non-RCT and RCTs were pooled (pooled HR =0.623, 95% CI =0.516-0.752, P,0.001) ( Figure 3C ).
sensitivity analysis and publication bias
Sensitivity analyses were performed using the leave-oneout approach (Figure 4) . For all outcomes, the direction and magnitude of the combined estimates did not vary markedly with the removal of one of the studies, indicating that the data were not overly influenced by each study. Publication bias was not assessed due to small sample size. 34 
Quality assessment
We assessed the study quality of the prospective studies included in this meta-analysis using the Cochrane Risk of Bias Tool (Figure 1 ). There were eight studies with potential selection bias for random sequence generation, and two studies had potential for allocation concealment bias. None of the included studies was double-blinded, and only two studies were blinded for outcome assessment ( Figure 1A ).
There were 11 studies with low risk in attrition bias and 15 studies with low risk of reporting bias. Overall, the quality of included studies was limited due to the study design and difficulty with blinding ( Figure 1B) . The described issues were partially related to the procedure used to administer the CIK cell therapy as well as the ethics behind patient allocation to treatment groups.
Discussion
The effectiveness of the current therapies for advanced HCC is limited, and the incidence of treatment-related adverse reactions is high, particularly in elderly patients with underlying liver conditions. 4 Therefore, new treatment modalities, capable of prolonging survival in patients with advanced HCC while minimizing the risk of adverse reactions, are urgently needed. Immunotherapy has a potential to offer systemic, nontoxic, and durable antitumor effects, and therefore is highly attractive as a treatment option for HCC. HCC tumor cells can be targeted by various immune effector mechanisms, 7 including by using CIK cells as effector cells. CIK cells belong to the T-cell population, display a T-celland NK cell-like phenotype, and are characterized by a nonmajor histocompatibility complex-restricted tumor killing activity. 7 Recently, a number of clinical trials have been undertaken to evaluate CIK cell-based immunotherapy in the treatment of HCC. To summarize and evaluate the most recent findings regarding the efficacy and safety of CIK cell immunotherapy as an adjuvant treatment for HCC, we performed the current meta-analysis.
We found that patients who underwent CIK cell-based immunotherapy had a higher rate of overall survival compared to patients who did not receive CIK cell-based therapy. The observed results were similar in both RCTs and non-RCTs. Additionally, patients who underwent CIK cell-based immunotherapy had lower rates of tumor recurrence. While we did not observe a statistically significant difference between the patients in the intervention and control groups regarding the PFS rate, the observed trend was in favor of CIK cell-based immunotherapy.
The studies included in this meta-analysis did not report adverse and unexpected side effects of the treatment. Several studies 16, 18, 26, 33 reported constitutional symptoms, such as fever and chills, in some patients who received therapy with CIK cells. Yu et al, 23 reported nausea in 4 patients in the CIK cell group and in 5 patients in the non-CIK cell group. One patient was allergic to CIK cells in the 2014 study by Guo et al. 33 Our meta-analysis is the most current, with rather broad inclusion parameters. We included RCTs and 
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Yu et al survival (OR =0.17, 95% CI =0.07-0.43, P,0.001), but not half-year survival (77% in the CIK cell group versus 67% in the non-CIK cell group; OR =0.43, 95% CI =0.05-3.94, P=0.45). CIK cell-based treatment was also associated with a significantly prolonged half-year and 1-year PFS (OR =0.29, 95% CI =0.16-0.52, P,0.001; OR =0.35, 95% CI =0.22-0.53, P,0.001, respectively). 35 We did not observe a significant improvement of PFS in the CIK cell treatment group in our meta-analysis, possibly due to differences in the study designs of the included studies, eg, number of RCTs versus non-RCTs. Recently, another meta-analysis assessed the efficacy of CIK cell therapy after TACE or TACE plus RFA and showed that CIK cell therapy combined with TACE plus RFA treatment was associated with a higher 1-year recurrence-free survival rate and 1-and 2-year OS rates. 36 While subgroup analysis based on the prior treatment was beyond the scope of our review, it should be further investigated in future studies. Furthermore, subgroup analysis based on other parameters, such as stage of cancer and exact therapeutic regimen, 
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ciK cell infusion for hepatocellular carcinoma would be beneficial in providing a better understanding of the effectiveness of immunotherapy and determining optimal therapeutic approaches for treatment of HCC.
The conclusions of this meta-analysis are subject to several limitations. Despite inclusion of non-English publications, the number of analyzed studies is limited, potentially leading to random errors. Another major drawback of the study is the moderate to large heterogeneity among the studies included for analysis of overall survival.
Conclusion
Our results highlight that adjuvant CIK cell-based immunotherapy is a promising therapeutic modality that can improve OS and reduce recurrence in patients with HCC. Future studies with subgroup analyses including etiologic factors, liver function, previous treatments, and disease stage should help to identify groups of HCC patients who would benefit the most from CIK cell-based immunotherapy.
